Argent BioPharma’s CannEpil® enters U.S. veterinary market as development programme commences
Argent BioPharma Ltd (ASX: RGT) has advised that Splash Beverage Group (NYSE American: SBEV), its exclusive global licensing partner for CannEpil®, has commenced a U.S. veterinary pharmaceutical development programme for the product.
The programme is being advanced through a strategic collaboration with Lupvindol Biosciences Ltd, which has been appointed to lead pharmaceutical development and FDA regulatory strategy.
Argent has described the appointment as the first operational milestone following the recently announced expansion of CannEpil® into veterinary healthcare. It establishes a defined regulatory development pathway for the product within the United States animal health market.
For investors, the development translates the company’s licensing-and-royalty strategy into tangible operational progress. Argent participates in the long-term commercial upside while its partner executes the development work.
When big ASX news breaks, our subscribers know first
Programme targets companion-animal oncology and chronic pain
The initial development focus is companion-animal oncology and chronic pain management, with canine applications expected to form the first stage of development.
Development activities will progress through the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA CVM). The regulatory pathway follows two defined stages:
-
Commencing with the Investigational New Animal Drug (INAD) process.
-
Progressing toward potential Conditional Approval through the FDA CVM.
A defined FDA pathway represents an important value-enhancing milestone that further validates the strategic expansion of the CannEpil® platform beyond its original human neurological indications.
Industry-leading cannabinoid development team behind the programme
The veterinary programme will be led by Dr. Hunter Land, Chief Executive Officer of Lupvindol Biosciences, together with an experienced cannabinoid pharmaceutical development team.
Dr. Land was the first full-time U.S. research and development employee of GW Pharmaceuticals and played an important role in the development of Epidiolex®, the world’s first FDA-approved plant-derived cannabinoid medicine, as well as Sativex®.
The broader Lupvindol team brings extensive experience across cannabinoid pharmaceutical development, FDA regulatory strategy, pre-clinical and clinical study design, product development and commercialisation.
Roby Zomer, Chairman
“We are extremely pleased to see the rapid execution of the strategy following the recent expansion of CannEpil® into veterinary healthcare. The appointment of Dr. Hunter Land and the Lupvindol Biosciences team brings one of the industry’s most experienced cannabinoid pharmaceutical development groups to the programme. Their involvement, including direct experience with the development of Epidiolex® and Sativex®, provides significant scientific and regulatory expertise as CannEpil® advances through the FDA veterinary pathway.”
Understanding CannEpil® and why the veterinary expansion matters
CannEpil® is a pharmaceutical-grade cannabinoid combination therapy formulated as a standardised 20:1 CBD:THC oral solution. It was developed for the management of drug-resistant epilepsy, also referred to as refractory epilepsy.
Argent notes that drug-resistant epilepsy affects approximately one-third of all epilepsy patients worldwide and remains one of the largest unmet needs in neurology.
The product has established regulatory and commercial access pathways across multiple jurisdictions, including Ireland, the United Kingdom, Germany and Australia. It is supported by real-world clinical evidence, peer-reviewed publications, EU-GMP manufacturing infrastructure and an active FDA IND programme in the United States.
CannEpil® has achieved full reimbursement status in Ireland under the Medicinal Cannabis Access Programme. The company recently completed the largest commercial shipment in the product’s history, with 1,000 units delivered into the Irish market.
That largest commercial shipment, worth approximately A$783,000 at full government reimbursement rates, demonstrated the commercial viability of the EU-GMP supply chain that underpins CannEpil’s multi-jurisdiction access strategy.
For investors, the veterinary programme extends the platform beyond its original neurological indications into a new market vertical, creating additional royalty opportunities.
| Element | Detail | Investor Impact |
|---|---|---|
| Licensing partner | Splash Beverage Group (NYSE American: SBEV) | Executes development; Argent participates via royalties |
| Development lead | Lupvindol Biosciences / Dr. Hunter Land | Deep FDA and cannabinoid pharma expertise |
| Initial focus | Companion-animal oncology and chronic pain (canine first) | New addressable market |
| Regulatory path | FDA CVM — INAD to Conditional Approval | Defined, value-enhancing pathway |
Argent retains ownership while sharing in the upside
A central feature of the arrangement is that Argent BioPharma continues to retain ownership of all existing and future CannEpil® intellectual property, manufacturing know-how and regulatory assets.
The CannEpil global licensing deal with Splash Beverage Group, which eliminated US$5.5 million in secured debt and established a 15% net revenue royalty structure for Argent, forms the contractual foundation on which this veterinary programme now sits.
At the same time, the company participates in the long-term commercial success of the product through royalties across both the human and veterinary healthcare markets. This frames a capital-efficient model, where the licensing partner executes development while Argent captures royalty upside.
The value retention can be summarised as follows:
-
IP ownership retained by Argent
-
Manufacturing know-how retained
-
Regulatory assets retained
-
Royalty participation across human and veterinary markets
The company believes the appointment of an experienced development partner, together with the commencement of a defined FDA regulatory pathway, represents an important value-enhancing milestone for the CannEpil® platform. It further validates the strategic expansion of the product beyond its original neurological indications.
What comes next for the CannEpil® platform
Development is set to commence with the INAD process before progressing toward potential Conditional Approval through the FDA CVM, with canine applications forming the first stage.
Argent positions itself as a next-generation specialty pharmaceutical company operating a capital-efficient model that combines proprietary intellectual property, commercial-stage products, strategic licensing, manufacturing services and recurring royalty income. The company has noted a clear pathway toward expansion into the United States capital markets.
As Chairman Roby Zomer stated, the milestone demonstrates that the global licensing strategy is already translating into tangible operational progress, with the licensing partner actively executing the next phase of development.
Don’t Miss the Next Healthcare Breakout on the ASX
Big News Blast delivers FREE breaking ASX healthcare news straight to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at Big News Blast to get the next market-moving announcement the moment it drops.